KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.95

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial.

Kalijn F Bol, Gerty Schreibelt, Martine Bloemendal, Wouter W van Willigen, Simone Hins-de Bree, Anna L de Goede, Annemiek J de Boer, Kevin J H Bos, Tjitske Duiveman-de Boer, Michel A M Olde Nordkamp, Tom G M van Oorschot, Carlijn J Popelier, Jeanne M Pots, Nicole M Scharenborg, Mandy W M M van de Rakt, Valeska de Ruiter, Wilmy S van Meeteren, Michelle M van Rossum, Sandra J Croockewit, Bouke J Koeneman, Jeroen H A Creemers, Inge M N Wortel, Caroline Angerer, Mareke Brüning, Katja Petry, Andrzej Dzionek, Astrid A van der Veldt, Dirk J van Grünhagen, Johanna E M Werner, Johannes J Bonenkamp, John B A G Haanen, Marye J Boers-Sonderen, Rutger H T Koornstra, Martijn F Boomsma, Erik H J Aarntzen, Martin Gotthardt, James Nagarajah, Theo J M de Witte, Carl G Figdor, Johannes H W de Wilt, Johannes Textor, Jan Willem B de Groot, Winald R Gerritsen, I Jolanda M de Vries

Nat Commun 15(1) 1632

PMID38395969
PMCIDPMC10891118
DOI10.1038/s41467-024-45358-0
发表日期2024-02-23
入排依据:The record is a Phase III randomized trial of a human oncology condition with time-to-event endpoints (RFS, OS) and reports a primary result. However, the intervention (autologous dendritic cell therapy) is a cell-based immunotherapy/biologic, not a conventional 'drug' (small molecule, antibody, etc.) as defined by the adjudication rules. Therefore, it fails the 'drug_intervention' criterion and is excluded.
摘要

摘要

Autologous natural dendritic cells (nDCs) treatment can induce tumor-specific immune responses and clinical responses in cancer patients. In this phase III clinical trial (NCT02993315), 148 patients with resected stage IIIB/C melanoma were randomized to adjuvant treatment with nDCs (n = 99) or placebo (n = 49). Active treatment consisted of intranodally injected autologous CD1c+ conventional and plasmacytoid DCs loaded with tumor antigens. The primary endpoint was the 2-year recurrence-free survival (RFS) rate, whereas the secondary endpoints included median RFS, 2-year and median overall survival, adverse event profile, and immunological response The 2-year RFS rate was 36.8% in the nDC treatment group and 46.9% in the control group (p = 0.31). Median RFS was 12.7 months vs 19.9 months, respectively (hazard ratio 1.25; 90% CI: 0.88-1.79; p = 0.29). Median overall survival was not reached in both treatment groups (hazard ratio 1.32; 90% CI: 0.73-2.38; p = 0.44). Grade 3-4 study-related adverse events occurred in 5% and 6% of patients. Functional antigen-specific T cell responses could be detected in 67.1% of patients tested in the nDC treatment group vs 3.8% of patients tested in the control group (p < 0.001). In conclusion, while adjuvant nDC treatment in stage IIIB/C melanoma patients generated specific immune responses and was well tolerated, no benefit in RFS was observed.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。